PUBLISHER: DelveInsight | PRODUCT CODE: 1125992
PUBLISHER: DelveInsight | PRODUCT CODE: 1125992
"REL-1017, Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about REL-1017 for Treatment Resistant Depression in seven major markets. A detailed picture of the REL-1017 for Treatment Resistant Depression in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the REL-1017 for Treatment Resistant Depression. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the REL-1017 market forecast analysis for Treatment Resistant Depression in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Treatment Resistant Depression.
REL-1017 (dextromethadone or D-methadone), a noncompetitive N-methylD-aspartate receptor (NMDAR) antagonist. NMDARs appear to be abnormally activated in depression. Whereas traditional antidepressants (such as selective serotonin reuptake inhibitors, serotonin-noradrenaline reuptake inhibitors, tricyclic antidepressants, and monoamine oxidase inhibitors) operate slowly, targeting the serotonin, noradrenaline, and dopamine-activated pathways, NMDAR antagonists are thought to act rapidly by correcting the imbalance between inhibitory GABAergic and excitatory glutamatergic activity in the brain cortical microcircuits. In addition, by inducing expression of the neuroprotective brain-derived neurotrophic factor (BDNF), NMDAR antagonists appear to produce a sustained antidepressant response, promoting synaptic plasticity and increasing the number of synaptic connections, which are decreased in depression and chronic stress.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
REL-1017 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of REL-1017 for Treatment Resistant Depression in seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
The report provides the clinical trials information of REL-1017 for Treatment Resistant Depression covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions